CD19 Deal Wave: Billions Committed as Targets Expand From Blood Cancers to Autoimmune Disease
Start here
The CD19 space has seen a burst of dealmaking and clinical progress over the past month, moving beyond hematologic malignancies into autoimmune disease. Simcere licensed its CD19 tri-specific antibody to Roche for $1.53 billion, and Abogen struck a deal worth up to $7.78 billion to bring its mRNA-CD19 T-cell engager to Novartis. On the science side, an in vivo CAR-T study was published in the New England Journal of Medicine, dual-target therapy produced strong data, and Bioray's allogeneic CD19 CAR-T entered a CDE pilot program for compassionate use in China. Open questions include how the licensed assets perform in development and whether the autoimmune expansion delivers on its promise.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comCD19 Surge: Multi-Billion-Dollar Deals Land as Field Pushes From Blood Cancers Into Autoimmune Disease
Over the past month, the CD19 space has kept heating up and expanded from hematologic malignancies into autoimmune disease. Simcere licensed its CD19 tri-specific antibody to Roche for 1.53 billion USD, and Abogen's mRNA-CD19 TCE went to Novartis in a deal worth up to 7.78 billion USD. An in vivo CAR-T study was published in NEJM, dual-target therapy showed strong data, and Bioray's allogeneic CD19 CAR-T entered a CDE pilot program for compassionate use.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 23 09:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.